Last reviewed · How we verify
NCT05289726
Study on the Prevention of Dermal Toxicity Caused by Regorafenib by Traditional Chinese Medicine TDX105
Phase 2 trial testing Traditional chinese medicine TDX105 in Hand and Foot Skin Reaction in 152 participants. Status unknown.
18 July 2022
Quick facts
| Lead sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 152 |
| Start date | 18 April 2022 |
| Primary completion | 18 July 2022 |
| Estimated completion | 18 April 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Traditional chinese medicine TDX105 — full drug profile →
- Placebo
Conditions studied
- Hand and Foot Skin Reaction — all drugs for Hand and Foot Skin Reaction →
- Colorectal Cancer Stage IV — all drugs for Colorectal Cancer Stage IV →
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Who can join
18 and older, any sex, with Hand and Foot Skin Reaction or Colorectal Cancer Stage IV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
this is an preventive study to evaluate the preventive effect of traditional chinese medicine TDX105 on Regorafenib induced Dermatologic Toxicities
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Prophylactic effect of the traditional Chinese medicine formula <i>danxiong</i> granules (TDX105) on hand-foot skin reaction associated with the antitumor targeted drug regorafenib: a randomized, double-blind, placebo-controlled trial.
Yu S, Hu X, Tan Y, Wang C, et al · · 2025 · PMID 41282614 · DOI 10.3389/fphar.2025.1641477
Verify or expand the search:
- PubMed search for NCT05289726
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials
Trials by the same sponsor.
- NCT07531563 — Protein Supplementation for Radiation- Induced Oral Mucositis in Head and Neck Cancer Patients Receiving Radiotherapy · NA · not yet recruiting
- NCT07537049 — BR101 in Patients With Relapsed/Refractory Multiple Myeloma · Phase 1 · not yet recruiting
- NCT07187154 — The Application of Symptoms Management Program Based on the Patient Reported Outcome After Esophagectomy · NA · not yet recruiting
- NCT07530549 — A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Che · Phase 2 · not yet recruiting
- NCT07507058 — Hypofractionated Radiotherapy for Postoperative Intermediate-Risk Head and Neck Squamous Cell Carcinoma · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05289726 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Last refreshed: 21 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05289726.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing